GeneDx (NASDAQ:WGS – Get Rating) and U.S. Physical Therapy (NYSE:USPH – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.
Institutional and Insider Ownership
56.0% of GeneDx shares are held by institutional investors. Comparatively, 98.4% of U.S. Physical Therapy shares are held by institutional investors. 29.3% of GeneDx shares are held by company insiders. Comparatively, 1.9% of U.S. Physical Therapy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares GeneDx and U.S. Physical Therapy’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GeneDx | -233.91% | -117.63% | -75.64% |
| U.S. Physical Therapy | 5.81% | 11.29% | 4.37% |
Volatility & Risk
Valuation & Earnings
This table compares GeneDx and U.S. Physical Therapy’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GeneDx | $234.69 million | 1.01 | -$548.98 million | ($0.93) | -0.32 |
| U.S. Physical Therapy | $553.14 million | 2.49 | $32.16 million | $2.25 | 46.78 |
U.S. Physical Therapy has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than U.S. Physical Therapy, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations and price targets for GeneDx and U.S. Physical Therapy, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GeneDx | 0 | 0 | 0 | 0 | N/A |
| U.S. Physical Therapy | 0 | 0 | 1 | 0 | 3.00 |
U.S. Physical Therapy has a consensus target price of $110.00, suggesting a potential upside of 4.50%. Given U.S. Physical Therapy’s higher probable upside, analysts clearly believe U.S. Physical Therapy is more favorable than GeneDx.
Summary
U.S. Physical Therapy beats GeneDx on 11 of the 13 factors compared between the two stocks.
About GeneDx
Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 Holdings Corp, formerly known as CM Life Sciences, is based in STAMFORD, Conn.
About U.S. Physical Therapy
U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics, which provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries. It operates through the following segments: physical therapy operations and industrial injury prevention services. The physical therapy operations segment consist of physical therapy and occupational therapy clinics that provide pre-and postoperative care and treatment for orthopedic related disorders, sports-related injuries, preventive care, rehabilitation of injured workers and neurological injuries. The injury prevention services segment includes onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments. U.S. The company was founded in 1990 and is headquartered in Houston, TX.
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
